Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Communications Chemistry|June 27, 2026
Structure and mechanism of inhibition of lysine demethylase 2A (KDM2A) by compound 183cPavel Mader, Linshan Liu, Frédéric Vallée, et al.Bioorganic & Medicinal Chemistry Letters|January 26, 2007
Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinonesElise Isabel, Renee Aspiotis, W Cameron Black, et al.ACS Medicinal Chemistry Letters|February 18, 2026
Design of a Targeted Covalent Probe to Interrogate the DNA Polymerase Activity of PolθMonica Bubenik, Pavel Mader, Stephen Orlicky, et al.Journal of Medicinal Chemistry|September 25, 2008
Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosisJöel Robichaud, W Cameron Black, Michel Thérien, et al.Journal of Medicinal Chemistry|February 3, 2006
Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin KSheldon N Crane, W Cameron Black, James T Palmer, et al.Bioorganic & Medicinal Chemistry Letters|January 18, 2006
Identification of a potent and selective non-basic cathepsin K inhibitorChun Sing Li, Denis Deschenes, Sylvie Desmarais, et al.Bioorganic & Medicinal Chemistry Letters|April 22, 2011
Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonistsDaniel Guay, Christian Beaulieu, Michel Belley, et al.Bioorganic & Medicinal Chemistry Letters|April 22, 2011
The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14Jacques Yves Gauthier, Michel Belley, Denis Deschênes, et al.Bioorganic & Medicinal Chemistry Letters|January 15, 2011
Difluoroethylamines as an amide isostere in inhibitors of cathepsin KElise Isabel, Christophe Mellon, Michael J Boyd, et al.Molecular Cancer Therapeutics|December 16, 2021
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP InhibitorsAnne Roulston, Michal Zimmermann, Robert Papp, et al.Pageof 7